Strumento inattivo

Altre lingue JHL Biotech, Inc.

Azioni

6540

KYG7863U1076

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.	10/05/22
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar	18/05/20
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma	27/12/18
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer	15/10/18
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer	10/08/18
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar	09/07/18
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma	05/07/18
JHL Biotech, Inc. Appoints Ellis Chu as Chief Financial Officer	13/06/18
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors	15/05/18
JHL Biotech Seeks Financing	30/03/18
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application	22/02/18
JHL Biotech, Inc.(GTSM:6540) dropped from S&P Global BMI Index	12/02/18
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.	05/02/18
JHL Biotech, Inc. announced that it expects to receive $150 million in funding	16/01/18
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis	20/12/17
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers	20/12/17
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials	05/04/17
JHL Doses First Patient In JHL1101 Phase I European Trial	29/03/17
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China	05/12/16
JHL Biotech, Inc. announced that it expects to receive TWD 2.55 billion in funding from Sanofi	05/12/16

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue JHL Biotech, Inc.

Azioni

6540

KYG7863U1076

Altre lingue

Filtri